Sign In
Buy GSK
$52.29
-0.490 (-0.93%)
At Close: Jul 13, 2026
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
09:31am, Tuesday, 14'th Jul 2026
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
10:25am, Monday, 13'th Jul 2026
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
09:30am, Monday, 13'th Jul 2026
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank r
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
03:15am, Monday, 13'th Jul 2026
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more a
GSK's targeted cancer therapy shows positive results in late-stage study
07:38am, Friday, 10'th Jul 2026
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Frida
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
05:20pm, Wednesday, 08'th Jul 2026
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
12:52am, Wednesday, 08'th Jul 2026
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
Is GSK Quietly Becoming An Oncology Powerhouse
09:36am, Thursday, 25'th Jun 2026
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong perform
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
03:41pm, Thursday, 18'th Jun 2026
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
10:55am, Thursday, 18'th Jun 2026
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
10:01am, Thursday, 18'th Jun 2026
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
04:21pm, Wednesday, 17'th Jun 2026
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
12:36pm, Wednesday, 17'th Jun 2026
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Uteb
